Changeflow GovPing Pharma & Drug Safety ACME UNITED CORPORATION Class II Recall D-0370-...
Urgent Enforcement Added Final

ACME UNITED CORPORATION Class II Recall D-0370-2026 for Towelettes

Favicon for changeflow.com FDA: Drug Recalls Class II
Filed March 11th, 2026
Detected March 28th, 2026
Email

Summary

The FDA has issued a Class II recall (D-0370-2026) for ACME UNITED CORPORATION's Cleansing Towelettes due to CGMP deviations. The recall is ongoing and affects nationwide distribution within the United States.

What changed

The FDA has initiated a Class II recall, designated D-0370-2026, for ACME UNITED CORPORATION's Cleansing Towelettes (Benzalkonium Chloride 0.13%) due to deviations from Current Good Manufacturing Practices (CGMP). The product, identified by NDC 0924-0243-00, was distributed nationwide.

Drug manufacturers and distributors involved in the supply chain of this product must immediately review their inventory and recall procedures. While specific compliance deadlines are not detailed in this notice, failure to comply with recall procedures can result in further enforcement actions by the FDA. Companies should ensure their CGMP compliance is up to standard to prevent similar issues.

What to do next

  1. Review inventory for affected Cleansing Towelettes.
  2. Implement recall procedures as per FDA guidelines.
  3. Verify CGMP compliance in manufacturing processes.

Source document (simplified)

ACME UNITED CORPORATION

Drug Recalls (Class II)

← All Drug Recalls (Class II) Class II D-0370-2026 · 20260311 · Ongoing

Product

Cleansing Towelette (Benzalkonium Chloride 0.13%), 5"x 7", 1,000 case/Bulk, Med-Nap, Brooksville, FL 34601, Made in USA, NDC 0924-0243-00.

Reason for Recall

CGMP Deviations

Distribution

Nationwide within the United States

Source: openFDA Enforcement API

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Filed
March 11th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0370-2026

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Recalls CGMP Compliance
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Product Safety Manufacturing Compliance

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when FDA: Drug Recalls Class II publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.